{
    "@graph": [
        {
            "@id": "https://www.tib.eu/de/suchen/id/TIBKAT%3A1046694944",
            "@type": "bibo:Book",
            "P1053": "1 Online-Ressource",
            "contributor": "Vernon, John A.",
            "creator": [
                "National Bureau of Economic Research",
                "Abbott, Thomas A."
            ],
            "description": "Campusweiter Zugriff (Universit\u00e4t Hannover) - Vervielf\u00e4ltigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots.",
            "identifier": [
                "(firstid)GBV:1046694944",
                "(ppn)1046694944",
                "(doi)10.3386/w11114"
            ],
            "publisher": "National Bureau of Economic Research",
            "subject": [
                "(classificationName=linseach:automatic)mat",
                "(classificationName=linseach:automatic)cet"
            ],
            "title": "The Cost of US Pharmaceutical Price Reductions : A Financial Simulation Model of R&D Decisions",
            "abstract": "Previous empirical studies that have examined the links between pharmaceutical price controls, profits, cash flows, and investment in research and development (R&D) have been largely based on retrospective statistical analyses of firm- and/or industry-level data. These studies, which have contributed numerous insights and findings to the literature, relied upon ad hoc reduced-form model specifications. In the current paper we take a very different approach: a prospective micro-simulation approach. Using Monte Carlo techniques we model how future price controls in the U.S. will impact early-stage product development decisions in the pharmaceutical industry. This is done within the context of a net present value (NPV) framework that appropriately reflects the uncertainty associated with R&D project technical success, development costs, and future revenues. Using partial-information estimators calibrated with the most contemporary clinical and economic data available, we demonstrate how pharmaceutical price controls will significantly diminish the incentives to undertake early-stage R&D investment. For example, we estimate that cutting prices by 40 to 50 percent in the U.S. will lead to between 30 to 60 percent fewer R&D projects being undertaken (in early-stage development). Given the recent legislative efforts to control prescription drug prices in the U.S., and the likelihood that price controls will prevail as a result, it is important to better understand the firm response to such a regulatory change",
            "dcterms:contributor": "Technische Informationsbibliothek (TIB)",
            "isPartOf": "(collectioncode)ZDB-194-NBW",
            "issued": "2005",
            "language": "http://id.loc.gov/vocabulary/iso639-1/en",
            "license": "open access",
            "medium": "rda:termList/RDACarrierType/1018",
            "volume": "no. w11114",
            "isLike": "doi:10.3386/w11114",
            "P30128": "NBER working paper series",
            "P60163": "Cambridge, Mass"
        }
    ],
    "@id": "urn:x-arq:DefaultGraphNode",
    "@context": {
        "isPartOf": "http://purl.org/dc/terms/isPartOf",
        "description": "http://purl.org/dc/elements/1.1/description",
        "P30128": "http://www.rdaregistry.info/Elements/m/#P30128",
        "abstract": "http://purl.org/dc/terms/abstract",
        "contributor": "http://purl.org/dc/elements/1.1/contributor",
        "P1053": "http://iflastandards.info/ns/isbd/elements/P1053",
        "medium": {
            "@id": "http://purl.org/dc/terms/medium",
            "@type": "@id"
        },
        "publisher": "http://purl.org/dc/elements/1.1/publisher",
        "creator": "http://purl.org/dc/elements/1.1/creator",
        "identifier": "http://purl.org/dc/elements/1.1/identifier",
        "language": {
            "@id": "http://purl.org/dc/terms/language",
            "@type": "@id"
        },
        "volume": "http://purl.org/ontology/bibo/volume",
        "license": "http://purl.org/dc/terms/license",
        "title": "http://purl.org/dc/elements/1.1/title",
        "isLike": {
            "@id": "http://umbel.org/umbel#isLike",
            "@type": "@id"
        },
        "issued": "http://purl.org/dc/terms/issued",
        "subject": "http://purl.org/dc/elements/1.1/subject",
        "P60163": "http://www.rdaregistry.info/Elements/u/#P60163",
        "umbel": "http://umbel.org/umbel#",
        "rdau": "http://www.rdaregistry.info/Elements/u/#",
        "owl": "http://www.w3.org/2002/07/owl#",
        "dcterms": "http://purl.org/dc/terms/",
        "bibo": "http://purl.org/ontology/bibo/",
        "rdam": "http://www.rdaregistry.info/Elements/m/#",
        "gnd": "http://d-nb.info/gnd/",
        "isbd": "http://iflastandards.info/ns/isbd/elements/",
        "rda": "http://rdvocab.info/",
        "doi": "https://doi.org/"
    }
}